Influence of Delayed Initiation of Cyclosporine on Everolimus Pharmacokinetics in de Novo Renal Transplant Patients

American Journal of Transplantation

Volumn 3, Issue 12, 2003, Pages 1576-1580

  Kovarik, John M ^a   Dantal, Jacques ^b   Civati, Giovanni ^c   Rizzo, Gaetano ^d   Rouilly, Marisel ^a   Bettoni Ristic, Olga ^a   Rordorf, Christiane ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HÔTEL DIEU   (France)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Cyclosporine; Drug interactions; Everolimus; Immunosuppression; Kidney transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A; EVEROLIMUS; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

CYCLOSPORINE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; SIROLIMUS; TIME FACTORS;

EID: 0346121383     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00242.x     Document Type: Article

References (10)

1. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative. Transplantation 1997; 64: 36-42.
2. Nashan B. Review of proliferation inhibitor everolimus. Expert Opin Invest Drugs 2002; 11: 1845-1857.
3. Valantine H, Eisen H, Dorent R et al. 12-month results of a multicenter study comparing efficacy and safety of everolimus to azathioprine in de novo cardiac transplantation. Am J Transplant 2002; 2: 247.
4. Kahan BD, Wong RL, Carter C et al. Phase 1 study of a 4-week course of SDZ-RAD in quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999; 68: 1100-1106.
5. Kovarik JM, Kaplan B, Tedesco-Silva H et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 2003; 3: 606-613.
6. Kovarik JM, Rouilly M, Rordorf C, Somberg K. Influence of cyclosporine on the pharmacokinetics of everolimus: searching for the interaction threshold in renal transplant patients. Am J Transplant 2002; 2: 186.
7. Kovarik JM, Kalbag J, Figueiredo J et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42: 95-99.
8. Kovarik JM, Kaplan B, Tesdesco Silva H et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920-925.
9. Kovarik JM, Sabia H, Rouilly M et al. Influence of renal and hepatic impairment on everolimus pharmacokinetics: are dose adjustments necessary? Am J Transplant 2001; 1: 385.
10. Rapamune (sirolimus). Physician's Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2001: 3443-3448.